**Horizon 1.5: Registry and Biorepository**

- **Participants consent to:**
  - Health and demographic questionnaire
  - Ongoing access to medical record
  - Brief exam (HR, BP, height, weight, waist circumference)
  - Blood and urine sample collection and consent for future use
  - Contact for annual follow-up and up to (4) times yearly to request participation in additional research studies
  - Indefinite participation (or until consent withdrawn)

- **More than 8000** participants living in Kannapolis/Cabarrus County, NC enrolled with continuing recruitment
  - Median duration of follow up: 1.6 (0.9, 2.3) years
  - Deaths during follow up: 34 (0.5%)
  - Withdrew from follow up: 26 (0.4%)

- **Over >250,000** biospecimens collected and banked
  - Processed and stored according to strict procedures
  - Paired with health surveys (baseline and annual follow up)
  - Linkage with EHR expected in 2012

- **Clinical ops in Kannapolis, NC (~24 FTEs)**
- Coordinated enrollment site network of 15+ providers plus use of churches, workplaces, schools as enrollment venues
- Representative sample planned: design methodology outlined and expert advisory board of internationally recognized epidemiologists convened

---

**Horizon 1**
- Generated molecular biosignatures using legacy samples
- Mined associated clinical data
- Generated hypotheses to reclassify diseases:
  - Liver disease
  - Cardiovascular disease
  - Osteoarthritis
  - Obesity

**Horizon 2**
- Prospective cohort studies
  - Multiple sclerosis
  - Alzheimer’s disease
  - Physical functioning
  - Severe acne
  - Centenarians
  - Drawing from subjects accessible via registry

**Horizon 3+**
- New waves of molecular data from diverse patient populations
- New cohort studies
- Data meta-analyses
- Multi-institutional and multi-national collaborations
- Measurement of public health impact

---

**Capabilities & Assets Available for Partnership:**

- **Thought leadership**
- **Readily accessible study populations and samples**
- **Well-annotated clinical data**
- **Site networks**

---

**Sample Type** | **Avg aliquots/volunteer**
--- | ---
Plasma | 16 x 500 µL
Buffy coat | Pulled from 2 EDTA tubes
Serum | 10 x 500 µL
Whole blood | 3 x 2 mL
Environmental (Serum) | 1 x 3 mL
PaxGene RNA | 3 tubes
Urine | 4 x 10 mL

---

*This list is not exhaustive.*

---


The MURDOCK Study is funded by the David H. Murdock Institute for Business and Culture and the Duke CTSA grant (UL1RR024128)